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The worldwide incidence of heart failure is steadily increasing over the past several
decades, partly due to population aging and improved survival of patients with cardio-
vascular diseases. Therefore the importance of biochemical substances raises which would
uncover ongoing cardiac overload, enable the treatment monitoring and make care of the
patients with heart failure more effective. According to the results of many clinical trials,
this task is fulﬁlled at most by natriuretic peptides which become gradually a part of
standard clinical practice. Both, brain natriuretic peptide and its N-terminal propeptide
help to detect heart failure in patients presenting with acute dyspnoea. Moreover, the
natriuretic peptide levels reﬂect the severity of the disease and can predict future clinical
outcomes in the heart failure patients. The role of natriuretic peptides as an objective
target for heart failure therapy in the outpatient care was not so well established.
The human recombinant brain natriuretic peptide nesiritide was approved in the
United States as a new therapeutic agent for acute heart failure. Although the ﬁrst results
were promising, questions regarding nephrotoxicity and possible higher mortality con-
nected with this substance avoided its broader therapeutic use to date.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Prevalence of chronic heart failure (HF) in general population
is about 1.3%. However, it substantially rises above the age of
75 where it reaches at least 8% and is one of the most
frequent causes of morbidity and mortality in this population
[1]. Every year, approximately 40,000 new cases of HF are
diagnosed in the Czech Republic. Over 40% of them die in
the following 4yr [2]. This represents signiﬁcant problem
for the healthcare system and the economy. One of the
most important goals in the management of HF is to
make the correct diagnosis early and to start the appropriate
treatment as soon as possible. Nevertheless, symptoms of
HF are unspeciﬁc and the typical clinical picture can be found
in less than 50% of the patients. The utilization of other
diagnostic methods, such as echocardiography, is often
limited. Consequently there is an increasing interest in new
biochemical markers that could be used for early and reliable
HF diagnostics, prediction of the clinical outcomes in HF
patients, as well as an objective measure of treatment effect.
The biomarkers also should be accessible at reasonable cost.
At present, such conditions are fulﬁlled at most by B-type
natriuretic peptide (BNP) and its N-terminal propeptide
(NT-proBNP), which became a substantial part of algorithms
for HF diagnosis [3]. Over the last years other biochemical
substances bring some novel information on HF patients.
Among the most promising belong mid-regional propeptides,
ST2-receptor for interleukin-33 and chromogranins which are
discussed elsewhere in this issue. The aim of this article is to
review information concerning the basic characteristics of
natriuretic peptides (NP) and their clinical use in HF.
2. Essential characteristics
B-type natriuretic peptide (BNP) was discovered in 1988. It was
originally isolated from porcine brain—that is the explanation for
generally used term “brain natriuretic peptide.” Afterwards,
it was found that the main source of BNP are cardiac myocytes,
the ventricular in larger quantity than the atrial [4]. The release
of BNP is triggered by increased myocardial wall stress due to
volume and/or pressure overload [5]. Natriuretic peptides realize
their effects through receptors connected with cyclic quanosine
monophosphate-depending signaling cascade in renal, suprar-
enal, vascular, cerebral and other tissues, which leads to diuresis,
natriuresis, inhibition of renin-angiotensin-aldosteron system
and vasodilatation. Ultimately, all these effects contribute to
blood pressure lowering. The antiproliferative effect of NP on
cardiac and vascular myocytes is also known well [6]. Recently,
Polak et al. reported increased lipolysis in abdominal adipose
tissue after the microdialysis perfusion with BNP in both, HF
patients and healthy subjects [7].
Natriuretic peptides are believed to have an important
protective role in pathophysiology of HF. In the case of body
volume overload the NP increase diuresis, keep the balance of
body salt and act as a counterweight of the renin-angiotensin-
aldosterone axis and the sympathetic nervous system effects.
Due to these abilities they can contribute to a longer asympto-
matic stage of the systolic left ventricular dysfunction. On the
other hand, the lack of an active form of BNP as well as BNPresistance because of down-regulation and inactivation of recep-
tors were described in patients with advanced HF [8].
Brain natriuretic peptide is synthesized in cardiac myo-
cytes as a precursor which is called proBNP. After a cell
stimulation by increased myocardial wall stress proBNP is
cleaved to the biologically active hormone (BNP) and to the
inactive N-terminal part of the molecule (NT-proBNP). Both
peptides are released to circulation. Brain natriuretic peptide
is eliminated from the body by clearance receptors, neutral
endopeptidase and renal ﬁltration. On the contrary, NT-
proBNP is cleared from circulation mainly by renal excretion.
Halftime of BNP is approximately 20 min; NT-proBNP has the
halftime of 60–120 min [9]. Plasma concentrations of both
peptides correlate to each other very well and they reach
similar levels within physiological conditions. Under the
circumstances of left ventricular dysfunction, NT-proBNP
plasma concentration rises exponentially and run to values
several times higher than BNP. The advantages of NT-proBNP
over BNP measurement are a longer biological halftime and
a higher stability which result in no need of immediate
assessment or deep freezing of the blood sample. On the
contrary, the renal insufﬁciency inﬂuences BNP less than its
N-terminal propeptide [10].3. Role in heart failure diagnostics
In spite of a substantial progress made in the treatment of HF,
the disease prognosis remains poor [11]. An early and appro-
priate diagnosis is very important, particularly at an emer-
gency department (ED). The evidence gathered during the
past 15 yr clearly demonstrates that both, the BNP and the
NT-proBNP plasma concentrations rise signiﬁcantly in the
patients with HF and correlate with their functional status
expressed by the New York Heart Association (NYHA) class
[10]. Many trials conﬁrmed the contribution of BNP and NT-
proBNP to clinical judgment for diagnosing acute HF in
dyspnoeic patients. The best known is the Breathing Not
Properly (BNP) study which comprised almost 1600 patients
presenting with acute breathlessness at the ED. According to
the results of this study the BNP plasma concentration below
100 pg/ml itself excludes the HF diagnosis with 90% sensitiv-
ity and together with clinical examination makes the estima-
tion of a cause of acute dyspnoea more accurate [12]. The
results of similar multinational trial with NT-proBNP were
also published [13]. Based on their ﬁndings the authors
established the NT-proBNP plasma level below 300 pg/ml to
rule out HF in breathlessness patients [13]. The cut off values
to conﬁrm the diagnosis of acute HF were not set uniformly.
According to the majority of studies BNP plasma concentra-
tions 4400 pg/ml and NT-proBNP 42000 pg/ml have high
positive predictive value for HF. This is why the past recom-
mendations enabled to set the diagnosis on the basis of high
NP levels [3]. Recently, the new ESC Guidelines for HF were
published [14]. In comparison with the previous one, NP
should serve now mainly as a tool for preselection of the
patients in whom echocardiography should be performed.
Echocardiography is supposed to be the ﬁnal conﬁrming
method in the HF diagnostic algorithm [14] (Fig. 1). Moreover,
the authors of the newer ESC Guidelines for HF recommended
Table 1 – Adjusted natriuretic peptide cut-offs according
to corresponding covariates.
Covariate BNP (pg/ml)
Heart failure 100
Age≥75 yr 184
Atrial ﬁbrillation 150
Creatinine≥2 mg/dl (177 μmol/l) 449
Body mass index≥35 (kg/m2) 25
BNP¼B-type natriuretic peptide. Freely adapted from [21].
Acute onset of HF 
symptoms and signs 
ECG, chest x-ray
Natriuretic peptides
ECG normal and 
BNP <100 pg/ml/
NT-proBNP < 300 pg/ml
ECG abnormal or
BNP≥400 pg/ml 
NT-proBNP≥300 pg/ml 
Echocardiography
HF diagnosis unlikely HF diagnosis 
confirmed/not confirmed
Fig. 1 – Diagnostic algorithm for patients with suspected heart failure. BNP¼B-type natriuretic peptide;
ECG¼electrocardiogram; HF¼heart failure; NT-proBNP¼N-terminal pro B-type natriuretic peptide. Freely adapted from [14].
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proBNP respectively) to rule out HF in patients with slow
onset of HF signs and symptoms which reﬂects lower NP
values among the patients presenting with the HF symptoms
in the primary care setting in comparison with the emer-
gency department [14].
There are several factors conducing to higher NP levels
besides failing heart ventricles. Age, renal insufﬁciency and
atrial ﬁbrillation belong to the most important ones [15–18].
The feasible mechanisms leading to elevation of NP concen-
trations are their lower clearance due to either a decreased
glomerular ﬁltration rate or a loss of clearance receptors with
aging, higher left atrial ﬁlling pressure and atrial dilatation
[5,19]. On the other hand, an inverse relationship between
BNP and body mass index was described [20]. Abundant
clearance receptors expressed in adipose tissue increase the
removal of NP from circulation and could thus contribute to
salt and water retention and consequently lead to early HF
manifestation in obese patients [20]. Therefore, some authors
recommended special BNP cut-offs in these situations to
secure its sensitivity and speciﬁcity [21] (Table 1). Similarly
to BNP, NT-proBNP plasma levels are inﬂuenced by age [15].
This resulted in the manufacturers recommendation of age-adjusted cut offs for the exclusion of acute HF (125 pg/ml for
the patients o75yr of age and 450 pg/ml for those ≥75yr of
age). However, the statistical analysis of the multicentre
study made by Januzzi et al. [13] showed that the single age
independent cut-off value of 300 pg/ml is superior to the age
dependant cut-off strategy.4. Prediction of prognosis
Natriuretic peptides could serve not only to assess the HF
diagnosis, but also for determination of the patient's prog-
nosis. The retrospective analysis of the data from the Val-
sartan in Heart Failure Trial (Val-HeFT), which included
patients with moderate to severe HF, showed a signiﬁcant
rise in the relative risk of mortality and morbidity through
out each quartile (o41 pg/ml, 41–97 pg/ml, 97–238 pg/ml,
4238 pg/ml) of BNP levels. Moreover, patients with the great-
est percent decrease of BNP values during the study had the
lowest mortality while the patients with the greatest percent
increase of BNP had the highest mortality [22]. In the
COPERNICUS NT-proBNP substudy the patients with severe
heart failure due to ischemic or non-ischemic cardiomyo-
pathy and NT-proBNP concentrations below 199 pg/ml had
substantially lower one-year mortality rate than those with
NT-proBNP above 504 pg/ml (3.9% vs. 27.9%) [23].
After hospitalization of a patient with acutely decompen-
sated HF the initial NP level can predict the patient's future
clinical outcome. Fonarow et al. reported that patients in the
highest quartile of BNP values on admission had the highest
in-hospital mortality, the highest probability of mechanical
ventilation, the longest time spent at intensive care unit as
well as in hospital at all [24]. In another study published
by Bettencourt et al., the prognosis of HF patients with
Fig. 2 – The relationship between achieved NT-proBNP level
and cardiovascular event rate in the ProBNP Outpatient
Tailored Chronic Heart Failure Therapy (PROTECT) study.
NT-proBNP¼N-terminal pro B-type natriuretic peptide.
Freely adapted from [26].
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hospitalization was signiﬁcantly better than that of patients
with no signiﬁcant change or even with an increase in
NT-proBNP concentrations, suggesting that these patients
really improved during hospitalization. Consequently, the
authors propose to take into account NP levels in timing of
the patient discharge [25].
As the ProBNP Outpatient Tailored Chronic Heart
Failure Therapy (PROTECT) study proved [26], the lower the
NT-proBNP plasma level was achieved by medical therapy in
patients with chronic HF, the lower the risk of cardiovascular
event these patients had (Fig. 2). Moreover, the authors identiﬁed
an inverse relationship between the time spent below the target
NT-proBNP concentration (1000 pg/ml) and the risk of cardiovas-
cular event [27].5. Management of heart failure therapy
As the incidence of HF and the number of HF hospitalizations
rises [1], the clinicians search for some objective target which
would help them to tailor the therapy of HF for each patient's
individual needs. Natriuretic peptides appear to be the most
suitable tool for this task. They correlate strongly with the
hemodynamic parameters such as pulmonary capillary wedge
pressure [28] and left ventricular end-diastolic pressure [29] and
therefore, reﬂect the actual hemodynamic status of the patients.
Moreover, the results of several studies proved the ability of HF
pharmacotherapy to lower NP plasma concentrations. Such an
effect was observed with angiotensin-converting enzyme inhi-
bitors (ACEi), angiotensin receptor antagonists, spironolacton,
diuretics and also with vasodilating betablockers during long-
term therapy [22,30–33]. The relationship between the decrease
of the BNP level and the improvement of patient's symptoms
during hospitalization suggests that intensifying HF therapy
guided by serial measurements of NP may bring better out-
comes [10]. The neurohumoral background for this theory was
set by Murdoch et al. [30] They observed more profound
inhibition of the RAAS and a signiﬁcant fall in heart rate in
the group of HF patients whose vasodilator therapy was titrated
according to plasma BNP compared to the patients with empirictherapy. After the successful pilot clinical study published by
Troughton et al., where the goal of reaching NT-proBNP values
below 200 pg/ml in symptomatic HF patients had positive
impact on number of cardiovascular events [31], several larger
trials with BNP and NT-proBNP guided therapy were initiated.
However, the results of these trials are ambiguous [27] (Table 2).
The STARS-BNP (Systolic Heart Failure Treatment Supported by
BNP) multicenter study comprised of 220 chronic HF patients,
who were randomized either to medical treatment according to
current guidelines or to therapy with the target of decreasing
BNP plasma concentrations below 100 pg/ml. After 15 months of
treatment signiﬁcantly fewer patients met the combined clinical
end point (hospitalization for HF or death related to HF) in the
BNP guided group [34]. On the contrary, in The Trial of
Intensiﬁed vs. Standard Medical Therapy in Elderly Patients
With Congestive Heart Failure (TIME-CHF) there was no differ-
ence in clinical outcomes between the group of patients treated
according to the NT-proBNP levels and the control group with
symptom guided therapy [35]. The BATTLESCARRED trial using
also NT-proBNP as a biomarker brought similar results [36].
Nevertheless, both studies showed that the therapy of chronic
HF according to plasma NP have positive impact on morbidity
and mortality in younger patients (o75 yr). The investigators try
to explain the effect difference depending on patient's age by
worse tolerability of intensiﬁed HF medication as well as higher
incidence of renal insufﬁciency in the elderly patients [36].
Recently, Felker et al. published a meta-analysis of six available
randomised controlled studies, including altogether 1627
patients, which tested the strategy of tailoring HF therapy
according to NP values. They clearly demonstrated that incor-
poration of this strategy into the clinical approach was con-
nected with signiﬁcant reduction of all-cause mortality [37]. In
the majority of published studies the NP guided therapy led to
more frequent adjustments of HF medication as compared to
symptoms guided therapy [37].6. Therapeutic use
Nesiritide is a human recombinant BNP which has similar
effects as the endogenous hormone. The intravenous infusion
causes venous, arterial and coronary vasodilatation and
consequently leads to reduction of preload, afterload and
improvement of cardiac output [38]. The hemodynamic and
clinical impact of nesiritide in comparison with nitroglycerine
and placebo was studied in the Vasodilation in the Manage-
ment of Acute CHF (VMAC) trial [38]. The results showed
greater decrease of pulmonary capillary wedge pressure
(PCWP) by nesiritide versus nitroglycerin but the patient's
self-assessment of dyspnea at 3 and 24h was similar in both
branches of the study. Despite unconvincing evidence, nesiri-
tide was approved by the U.S. Food and Drug Administration
for relief of dyspnea in patients with acute decompensated HF
which led to excessive use of nesiritide not only in the hospital
acute HF care but also in the outpatient setting across the
United States. Later, Sackner-Bernstein JD et al. Analyzed 3
randomized trials with the recombinant BNP therapy in acute
decompensated HF patients. They found out a trend to higher
30 day mortality (hazard ratio 1.8; 95% CI 0.97–3.12; p¼0.059)
and a signiﬁcantly increased risk of worsening renal functions
Table 2 – Overview of natriuretic peptide guided treatment studies.
Trial (according to
date of publication)
HF-PEF Target NP level (pg/ml) Primary clinical endpoint(s) Result Lower NP level at
the end of the trial a
Troughton [31] No NT-proBNPo1735 Total CV events Positive Yes
STARS-BNP [34] No BNPo100 Death or hospitalization related
to HF.
Positive Unknown
TIME-CHF [35] No NT-proBNPo400/800 (for
ageo75/≥75 years)
Survival free of all-cause
hospitalizations; Quality of life
Negative No
BATTLESCARRED
[36]
Yes NT-proBNPo1270 All cause mortality; Death
+hospitalization for HF
Negative No
PRIMA [43] Yes NT-proBNP-individual value
at hospital discharge
Number of days alive outside
the hospital
Negative No
SIGNAL-HF [44] No NT-proBNP≤50% below trial
entry
Days alive+days out of hospital
+symptom score
Negative No
STARBRITE [45] No BNP-individual value at
hospital discharge
Number of days alive and not
hospitalized
Negative No
PROTECT [26] No NT-proBNPo1000 Total CV events Positive Yes
BNP¼B-type natriuretic peptide; CV¼cardiovascular; HF¼heart failure; HF-PEF¼heart failure with preserved ejection fraction; NP¼natriuretic
peptide; NT-proBNP¼N-terminal pro B-type natriuretic peptide.
a Natriuretic peptide plasma level in the active arm compared to the control arm.
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inotrop based controls [39,40]. Recently, the large multicentre
Acute Study of Clinical Effectiveness of Nesiritide and Decom-
pensated Heart Failure (ASCEND-HF) was presented compris-
ing 7141 acute HF patients receiving either nesiritide or
placebo. No signiﬁcant difference was found either in 30-day
mortality from any cause or in the rates of worsening renal
functions between the two groups. Moreover, nesiritide had
only a small, statistically non-signiﬁcant inﬂuence on dyspnea
improvement [41]. The investigators concluded that nesiritide
cannot be recommended for routine use in wide population of
patients with acute HF [41].
Ularitid is a recombinant form of urodilatin, the natriuretic
peptide synthesized by the kidney which is involved in body
salt and water regulation. The SIRIUS II study regarding the
clinical effect of ularitide infusions in patients with acute
decompensated heart failure proved the reduction of PCWP as
well as the improvement of dyspnoea 6 h after the completion
of the 24 h infusion. In higher doses, ularitide also decreased
systemic vascular resistance and increased cardiac output in
these patients [42]. Nevertheless, further clinical trials are
necessary to conﬁrm the clinical signiﬁcance of ularitide in
comparison with standard therapy of acute heart failure.7. Conclusion
In conclusion, natriuretic peptides proved their added value to
clinical judgement and echocardiography for diagnosing HF in
the patients with acute breathlessness. Once the appropriate
diagnosis is established, the NP plasma concentrations of the
individual patient reﬂect his/her current hemodynamic status
and can predict future clinical outcomes. The role of NP in
tailoring HF therapy was yet not proved unambiguously and
still needs further clinical investigation. Similarly, the ther-
apeutic use of human recombinant BNP nesiritide remains
controversial.Acknowledgments
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